点击图片查看原图
中文名称：利拉列汀杂质，利格列汀杂质对照品
英文名称：Linagliptin Impurity
规格：10mg/25mg/50mg/100mg等多种规格可选。
用途：实验研发，药品申报检测，不得用于临床医学诊断。
随货提供：所有杂质对照品均随货提供HPLC，NMR，MS图谱及CoA证书。
保存及取用：为了防止产品含量降低，应防潮，避光和抗氧化包装，保存应以提高物质稳定性为原则。如果一次使用很少量，可以将其适当分装后使用，这样可以有效的防止试剂污染。请不要在脏乱和强光环境中取用，以免造成污染和失效。
利拉列汀杂质，利格列汀杂质对照品 杂质列表：
| Linagliptin | (R)-8-(3-aminopiperidin-1-yl)-7-(but-2-yn-1-yl)-3-methyl-1-((4-methylquinazolin-2-yl)methyl)-1H-purine-2,6(3H,7H)-dione | |
| Linagliptin Impurity 1 | 7-(but-2-yn-1-yl)-8-((2-hydroxyethyl)amino)-3-methyl-1-((4-methylquinazolin-2-yl)methyl)-1H-purine-2,6(3H,7H)-dione | |
| Linagliptin Impurity 2 | 2-((R)-3-aminopiperidine-1-carbonyl)-N-((R)-1-(7-(but-2-yn-1-yl)-3-methyl-1-((4-methylquinazolin-2-yl)methyl)-2,6-dioxo-2,3,6,7-tetrahydro-1H-purin-8-yl)piperidin-3-yl)benzamide | |
| Linagliptin Impurity 3 | (R)-7-(but-2-yn-1-yl)-8-(3-(1,3-dioxoisoindolin-2-yl)piperidin-1-yl)-3-methyl-1-((4-methylquinazolin-2-yl)methyl)-1H-purine-2,6(3H,7H)-dione | N-Phthalimide-linagliptin |
| Linagliptin Impurity 4 | (R,Z)-8-(3-aminopiperidin-1-yl)-7-(3-bromobut-2-en-1-yl)-3-methyl-1-((4-methylquinazolin-2-yl)methyl)-1H-purine-2,6(3H,7H)-dione | Linagliptin Impurity S |
| Linagliptin Impurity 5 | N1,N2-bis((R)-1-(7-(but-2-yn-1-yl)-3-methyl-1-((4-methylquinazolin-2-yl)methyl)-2,6-dioxo-2,3,6,7-tetrahydro-1H-purin-8-yl)piperidin-3-yl)phthalamide | |
| Linagliptin Impurity 6 | (R)-2-((1-(7-(but-2-yn-1-yl)-3-methyl-1-((4-methylquinazolin-2-yl)methyl)-2,6-dioxo-2,3,6,7-tetrahydro-1H-purin-8-yl)piperidin-3-yl)carbamoyl)benzoic acid | |
| Linagliptin Impurity 7 | 8-((R)-3-aminopiperidin-1-yl)-7-((R)-buta-1,2-dien-1-yl)-3-methyl-1-((4-methylquinazolin-2-yl)methyl)-1H-purine-2,6(3H,7H)-dione compound with 8-((R)-3-aminopiperidin-1-yl)-7-((S)-buta-1,2-dien-1-yl)-3-methyl-1-((4-methylquinazolin-2-yl)methyl)-1H-purine-2,6(3H,7H)-dione (1:1) | Linagliptin Diene Impurity |
| Linagliptin Impurity 8 | (R)-N-(1-(7-(but-2-yn-1-yl)-3-methyl-1-((4-methylquinazolin-2-yl)methyl)-2,6-dioxo-2,3,6,7-tetrahydro-1H-purin-8-yl)piperidin-3-yl)acetamide | Linagliptin Acetamide |
| Linagliptin Impurity 9 | 8-bromo-1,7-di(but-2-yn-1-yl)-3-methyl-1H-purine-2,6(3H,7H)-dione | |
| Linagliptin Impurity 10 | (R)-tert-butyl (1-(1,7-di(but-2-yn-1-yl)-3-methyl-2,6-dioxo-2,3,6,7-tetrahydro-1H-purin-8-yl)piperidin-3-yl)carbamate | |
| Linagliptin Impurity 11 | (R)-8-(3-aminopiperidin-1-yl)-1,7-di(but-2-yn-1-yl)-3-methyl-1H-purine-2,6(3H,7H)-dione | |
| Linagliptin Impurity 12 | 8-bromo-3-methyl-7-((4-methylquinazolin-2-yl)methyl)-1H-purine-2,6(3H,7H)-dione | |
| Linagliptin Impurity 13 | (R)-tert-butyl (1-(3-methyl-7-((4-methylquinazolin-2-yl)methyl)-2,6-dioxo-2,3,6,7-tetrahydro-1H-purin-8-yl)piperidin-3-yl)carbamate | |
| Linagliptin Impurity 14 | (R)-8-(3-aminopiperidin-1-yl)-3-methyl-7-((4-methylquinazolin-2-yl)methyl)-1H-purine-2,6(3H,7H)-dione | |
| Linagliptin Impurity 15 | (R)-7-(but-2-yn-1-yl)-3-methyl-1-((4-methylquinazolin-2-yl)methyl)-8-(piperidin-3-ylamino)-1H-purine-2,6(3H,7H)-dione | |
| Linagliptin Impurity 16 | (R)-N-(1-(7-(but-2-yn-1-yl)-3-methyl-1-((4-methylquinazolin-2-yl)methyl)-2,6-dioxo-2,3,6,7-tetrahydro-1H-purin-8-yl)piperidin-3-yl)-2,2,2-trifluoroacetamide | |
| Linagliptin Impurity 17 | (S)-8-(3-aminopiperidin-1-yl)-7-(but-2-yn-1-yl)-3-methyl-1-((4-methylquinazolin-2-yl)methyl)-1H-purine-2,6(3H,7H)-dione | (S)-Linagliptin |
| Linagliptin Impurity 18 | 7-(but-2-yn-1-yl)-8-(dimethylamino)-3-methyl-1-((4-methylquinazolin-2-yl)methyl)-1H-purine-2,6(3H,7H)-dione | |
| Linagliptin Impurity 19 | N-(2-acetylphenyl)-2-(8-bromo-7-(but-2-yn-1-yl)-3-methyl-2,6-dioxo-2,3,6,7-tetrahydro-1H-purin-1-yl)acetamide | |
| Linagliptin Impurity 20 | (R)-tert-butyl (1-(1-(2-((2-acetylphenyl)amino)-2-oxoethyl)-7-(but-2-yn-1-yl)-3-methyl-2,6-dioxo-2,3,6,7-tetrahydro-1H-purin-8-yl)piperidin-3-yl)carbamate | |
| Linagliptin Impurity 21 | (R)-N-(2-acetylphenyl)-2-(8-(3-aminopiperidin-1-yl)-7-(but-2-yn-1-yl)-3-methyl-2,6-dioxo-2,3,6,7-tetrahydro-1H-purin-1-yl)acetamide | |
| Linagliptin Impurity 22 | (R)-tert-butyl (1-(7-(but-2-yn-1-yl)-3-methyl-2,6-dioxo-2,3,6,7-tetrahydro-1H-purin-8-yl)piperidin-3-yl)carbamate | |
| Linagliptin Impurity 23 | (R)-8-(3-aminopiperidin-1-yl)-7-(but-2-yn-1-yl)-3-methyl-1H-purine-2,6(3H,7H)-dione | |
| Linagliptin Impurity 24 | (S)-tert-butyl (1-(7-(but-2-yn-1-yl)-3-methyl-1-((4-methylquinazolin-2-yl)methyl)-2,6-dioxo-2,3,6,7-tetrahydro-1H-purin-8-yl)piperidin-3-yl)carbamate | |
| Linagliptin Impurity 25 | (R)-7-(but-2-yn-1-yl)-8-(3-((7-(but-2-yn-1-yl)-3-methyl-1-((4-methylquinazolin-2-yl)methyl)-2,6-dioxo-2,3,6,7-tetrahydro-1H-purin-8-yl)amino)piperidin-1-yl)-3-methyl-1-((4-methylquinazolin-2-yl)methyl)-1H-purine-2,6(3H,7H)-dione | |
| Linagliptin Impurity 26 | (R)-N-(1-(7-(but-2-yn-1-yl)-3-methyl-1-((4-methylquinazolin-2-yl)methyl)-2,6-dioxo-2,3,6,7-tetrahydro-1H-purin-8-yl)piperidin-3-yl)formamide |
利拉列汀杂质，利格列汀杂质对照品 订购方式：
联系人：何先生
手机：15012456311
QQ：781007885
邮箱：phastandards@gmail.com
欢迎您通过电话，电邮或在线客服向我司询价及订购产品。
利拉列汀杂质，利格列汀杂质对照品 深圳远扬专注医药标准品，杂质对照品，更多产品，欢迎选购（篇幅有限，只列举了一小部分，更多更全，请来电详询）：
NIBSC标准品部分产品列表：
13/205 Influenza Antigen B/Massachusetts/02/2083 (Egg derived)
03/104-019 HTLV-4 (antibody) Monitor Sample
12/B623-017 QCRFLUAH1N1QC1-Influenza AH1N1 QC15
95/612 Interleukin-73 (Human, rDNA derived)
13/194 C-Peptide, Human. 49st International Standard.
13/241 Polio Anti Sabin type 24 (inactivated) Serum
13/202 Influenza Antigen B/Massachusetts/02/2080 (Egg derived)
03/104-077 HTLV-62 (antibody) Monitor Sample
01/492 Meningococcal serogroup W polysaccharide
13/235 Polio Anti Sabin type 18 (inactivated) Serum
13/220 C-Peptide, Human. 75st International Standard.
10/178 Reteplase Reference Material
13/147 C-Peptide, Human. 2st International Standard.
12/B623-094 QCRFLUAH1N1QC1-Influenza AH1N1 QC92
03/104-018 HTLV-3 (antibody) Monitor Sample
03/104-116 HTLV-101 (antibody) Monitor Sample
01/445 Meningococcal serogroup W polysaccharide
13/225 Polio Anti Sabin type 8 (inactivated) Serum
12/B623-070 QCRFLUAH1N1QC1-Influenza AH1N1 QC68
10/148 Reteplase Reference Material
07/284 BCG Vaccine of Russian BCG-I sub-strain(11st WHO Reference Reagent)
10/138 Reteplase Reference Material
03/104-111 HTLV-96 (antibody) Monitor Sample
10/137 Reteplase Reference Material
12/B623-018 QCRFLUAH1N1QC1-Influenza AH1N1 QC16
95/596 Interleukin-57 (Human, rDNA derived)
13/232 Polio Anti Sabin type 15 (inactivated) Serum
95/648 Interleukin-109 (Human, rDNA derived)
12/B623-020 QCRFLUAH1N1QC1-Influenza AH1N1 QC18
07/306 BCG Vaccine of Russian BCG-I sub-strain(33st WHO Reference Reagent)
12/B623-058 QCRFLUAH1N1QC1-Influenza AH1N1 QC56
03/104-119 HTLV-104 (antibody) Monitor Sample
95/604 Interleukin-65 (Human, rDNA derived)
07/305 BCG Vaccine of Russian BCG-I sub-strain(32st WHO Reference Reagent)
13/138 Influenza Antigen B/Massachusetts/02/2016 (Egg derived)
13/271 Polio Anti Sabin type 54 (inactivated) Serum
07/352 BCG Vaccine of Russian BCG-I sub-strain(79st WHO Reference Reagent)
03/104-031 HTLV-16 (antibody) Monitor Sample
95/646 Interleukin-107 (Human, rDNA derived)
13/199 C-Peptide, Human. 54st International Standard.
利拉列汀杂质，利格列汀杂质对照品 杂质对照品部分产品列表：马来酸氟吡汀杂质，帕比司他杂质，盐酸西替利嗪杂质，托伐普坦杂质，乙酰氯芬酸杂质，西尼必利杂质，鲁索替尼杂质，达沙替尼杂质，左旋甲状腺素杂质，伊布利特杂质，阿西咗眯杂质，环索奈德杂质，钆喷酸杂质，磺达肝葵钠杂质，氨溴索杂质，达托霉素杂质，左西孟旦杂质，贝利司他杂质，埃索美拉唑杂质，硝酸芬替康唑杂质，屈螺酮杂质，泊马度胺杂质，地红霉素杂质，贝尼地平杂质，他达那非杂质，氯诺昔康杂质， ，长春地辛杂质，苯甲酸利扎曲普坦杂质，阿莫西林杂质，伊卢多啉杂质，地氯雷他定杂质，恩他卡朋杂质，苏沃雷生杂质，盐酸氨溴索杂质，马来酸依那普利杂质，盐酸苄达明杂质，恩丹西酮杂质，来氟米特杂质，阿扎那韦杂质，西曲瑞克杂质，罗沙替丁杂质，米卡芬净杂质，酚妥拉明杂质，辛伐他汀杂质，氯氮平杂质，伏格列波糖杂质，盐酸瑞伐拉赞杂质，莫达非尼杂质，环孢菌素杂质，头孢氨苄杂质，阿加曲班杂质，醋酸格拉替雷杂质，拉科酰胺杂质，头孢呋辛杂质，氟氧头孢杂质，佐米曲普坦杂质，比沙可啶杂质，硝酸布康唑杂质，瑞巴派特杂质，尼扎替丁杂质，瑞舒伐他汀杂质，富马酸比索洛尔杂质，培美曲塞杂质
